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Abstract: Our previous study showed that chromosome region 
maintenance 1 (CRM1), a nuclear export receptor for various 
cancer-associated “cargo” proteins, was important in regulat-
ing lung carcinogenesis in response to a tobacco carcinogen, 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). The 
objectives of this study are to comprehensively evaluate the sig-
nificance of CRM1 in lung cancer development and investigate the 
therapeutic potential of targeting CRM1 for lung cancer treatment 
using both in vitro and in vivo models. We showed that CRM1 was 
overexpressed not only in lung tumor tissues from both lung cancer 
patients and mice treated with NNK but also in NNK-transformed 
BEAS-2B human bronchial epithelial cells. Furthermore, stable 
overexpression of CRM1 in BEAS-2B cells by plasmid vector 
transfection led to malignant cellular transformation. Moreover, a 
decreased CRM1 expression level in A549 cells by short hairpin 
siRNA transfection led to a decreased tumorigenic activity both in 
vitro and in nude mice, suggesting the potential to target CRM1 
for lung cancer treatment. Indeed, we showed that the cytotoxic 
effects of cisplatin on A549 cells with CRM1 down-regulated by 
short hairpin siRNA were significantly increased, compared with 
A549 cells, and the cytotoxic effects of cisplatin became further 
enhanced when the drug was used in combination with leptomycin 
B, a CRM1 inhibitor, in both in vitro and in vivo models. Cancer 
target genes were significantly involved in these processes. These 
data suggest that CRM1 plays an important role in lung carci-
nogenesis and provides a novel target for lung cancer adjuvant 
therapy.
Key Words: Lung cancer, CRM1, p53, Leptomycin B, Combination 
therapy.
(J Thorac Oncol. 2015;10: 815–825)
Lung cancer continues to be the leading cause of cancer deaths in the US and worldwide.1,2 Non–small-cell lung 
cancer (NSCLC) remains the predominant form of lung can-
cer (approximately 85%).3,4 With some improvements in sur-
gical techniques and combined therapies over the past several 
decades, the relative survival rate for lung cancer has increased 
slightly. However, lung cancer remains extremely lethal, with 
a 5-year survival rate of only about 15% in the US.2 Unclear 
molecular mechanisms, lack of early diagnostic biomarkers, 
and deficiency of targeted therapy in lung cancer are some of 
the major reasons that its incidence, diagnosis, and prognosis 
remain relatively unchanged.
Evidence shows that 80–90% of lung cancers are 
directly or indirectly traceable to tobacco use.5–7 More than 60 
known carcinogens have been identified in cigarette smoke,8,9 
among which N-nitrosamines play major roles in carcino-
genesis. NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
none] is an important nitrosamine with highly carcinogenic 
activities and a consistent presence in relatively considerable 
amounts in cigarette smoke.8 NNK has been shown to have 
lung-selective toxicity and induce primarily lung adenocarci-
noma in a variety of laboratory animals.6,9 The development 
of lung cancer has been extensively investigated in the past 
40 years. Some of these studies, including our previous stud-
ies,10–12 have revealed a frequent occurrence of mutations in 
several proto-oncogenes and tumor suppressor genes, includ-
ing p53 gene, and such alterations have been associated with 
the initiation and progression of lung cancer.
In addition to mutations in oncogenes and tumor sup-
pressor genes, accumulated evidence has also shown that 
stage-specific genes turn on or off during the process of 
cancer development.13 For instance, in eukaryotic cells 
nuclear-cytoplasmic transport is critical for normal biological 
functions, such as transcription and cell cycle regulation.14,15 
Chromosome region maintenance 1 (CRM1), the best char-
acterized nuclear export receptor, was first identified in the 
yeast Schizosaccharomyces prombe16 and has been found 
as a conserved gene in eukaryotes. CRM1 protein, facili-
tated by Ran, plays an essential role in nuclear export signal 
(NES)-dependent nuclear export of various cancer-associated 
“cargo” proteins,17–20 including both tumor suppressors and 
pro-oncogenes, which control genomic stability, cell cycle 
arrest, and apoptosis, such as p53, epidermal growth factor 
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receptor (EGFR), protein kinase 1 (Akt1), survivin, and so on. 
The structure of CRM1 protein contains a highly conserved 
central region involved in RanGTP-dependent NES recogni-
tion and cysteine residue covalently modified by leptomycin 
B (LMB).21 LMB, an antifungal agent, is a highly specific and 
potent inhibitor of CRM1 function by irreversibly reacting 
with a Cys residue (Cys529) near or within the cargo binding 
domain of CRM1.22 Elevated CRM1 protein expression has 
been identified in various human tumors,23–27 but no study has 
been conducted on lung cancer.
Data from our previous studies have suggested that 
decreased CRM1 plays an important role in the initial response 
of lung epithelial cell to tobacco carcinogen and the tumor for-
mation of a bi-transgenic lung tumor model.28,29 To get further 
insight into the mechanisms by which CRM1 is involved in 
late phase of lung cancer development, in this study we have 
analyzed CRM1 expression in lung tumor tissues from lung 
cancer patients, lung cancer cells, and NNK-treated mice and 
human lung epithelial cells. In addition, the therapeutic poten-
tial of targeting CRM1 in lung cancer was also investigated.
MATERIALS AND METHODS
Tissue Specimens and TMA
Lung cancer tissues consisted of paraffin-embedded 
lung tumors including five adenocarcinomas and five squa-
mous cell carcinomas. These patients were all smokers and 
consisted of nine males and one female, with an age range 
of 26–78 years. All slides were stained with hematoxylin and 
eosin and reviewed by a pathologist to confirm the histological 
presence of tumor. This set of samples was used as a train-
ing set to evaluate CRM1 expression in lung cancer tissues 
as compared with matched adjacent histologically normal 
tissues.
Tissue microarray (TMA) was purchased from 
IMGENEX and was made from 59 lung cancer tissues (IMH-
305) or their matching normal adjacent tissues (IMH-340). 
These specimens were obtained from 47 males and 12 females 
with an average age of 60.8 years (range 33–81). They con-
sisted of 15 adenocarcinomas (seven stage I, four stage II, and 
four stage III), 37 squamous cell carcinomas (12 stage I, 19 
stage II, and six stage III), five large cell carcinomas (four 
stage I and one stage II), and two carcinosarcomas (one stage 
I and one stage II). This set of samples was used as a testing 
set to validate the finding of CRM1 expression.
Immunohistochemistry and 
Immunocytochemistry
The signals of CRM1 or p53 were evaluated by immuno-
histochemistry or immunocytochemistry using VECTASTAIN 
ABC Kit with DAB as the substrate (Vector Laboratories, 
Burlingame, CA) following the manufacturer’s protocol with 
modification as described in our previous publications.28,29 To 
evaluate CRM1 expression in samples from the training set, 
stained lung tissue sections were semi-quantified using the “H 
score” as described in our previous study.28 Different from the 
qualitative analysis for the training set, a quantitative measure-
ment of the CRM1 staining (range 0–3: “zero” designates no 
stain, and “three” defines the darkest stain) was performed for 
the testing set of samples from TMA. The slides were blindly 
examined by two individuals.
Human Normal Lung Epithelial Cells 
BEAS-2B, NNK Exposure/Transformation, 
and CRM1 Stable Overexpression
Human normal bronchial epithelial cell line BEAS-2B 
was obtained from American Type Culture Collection. (1) For 
short-term NNK exposure, BEAS-2B cells were treated with 
0, 10, 75, or 150 μM NNK for 24 and 72 h in triplicate as 
described in our previous study29; (2) BEAS-2B
NNK
, an in vitro 
transformed cell model derived from BEAS-2B, was generated 
by exposure to NNK (15 μM) for 24 h and then continuously 
sub-cultured for nine passages. This transformed cell has been 
shown to be suitable for studying lung carcinogenesis30; and (3) 
BEAS-2B with stably overexpressed CRM1, named BEAS-
2B
CRM1+
, was generated by CRM1 expression plasmid con-
struct transfection (RC206004, OriGene, Rockville, MD) and 
G418 (Invitrogen, Grand Island, NY) selection in BEAS-2B 
cells. Similarly, BEAS-2B was transfected with vector control 
for comparison. BEAS-2B, BEAS-2B
NNK
, and BEAS-2B
CRM1+
 
cells were cultured in LHC-9 medium (Invitrogen) containing 
100 U penicillin/ml and 100 μg/ml streptomycin.
CRM1 Stable Knockdown in 
A549 Cells (A549CRM1-)
We have designed CRM1-siRNA oligonucleotides and 
their efficacy for knocking down CRM1 was compared with 
that of commercially available CRM1-siRNA from Santa 
Cruz Biotechnology (Santa Cruz, CA). A short hairpin siRNA 
was designed using one specific effective siRNA for stable 
transfection. After transformation, selection, propagation, 
purification, and sequencing, the purified pSilencer 4.1-CMV 
plasmid was transfected into A549 cells. The stable trans-
fected cells were selected by the culture medium containing 
1 mg/ml G418 (Invitrogen). Similar approach was used for the 
control with a scrambled short hairpin siRNA.
Soft Agar Colony Assay (Anchorage-
Independent Growth Assay)
Cells were suspended at 5 × 104 cells/ml for BEAS-2B, 
BEAS-2B
 NNK
, and BEAS-2B
CRM1+
 or 2 × 104 cells/ml for A549 
and A549
CRM1-
 in growth medium containing 0.35% agar. Cell 
suspension was added to a six-well tissue culture plate precoated 
with 0.7% solid agar. After 9–11 days of incubation (9 days for 
A549 and 11 days for BEAS-2B), the number of colonies/micro-
scope area (six randomly selected areas/well) was counted and 
their sizes were analyzed using cell staining (0.005% crystal vio-
let) by microscope. This experiment was done in triplicate.
NNK-Induced Mouse Lung Tumors
Male FVB/N mice are an intermediately susceptible strain 
with regard to spontaneous lung tumor formation and have been 
used for studies of NNK-induced lung tumorigenesis.31 Mice 
were each given two intra-peritoneal injections of 3 mg NNK 
per week (NNK-treated group, n = 8) or 0.9% saline (vehicle 
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control group, n = 8). From each group, mice were sacrificed at 
32 weeks after the last NNK- or saline-treatment. Lung tissues 
were fresh frozen or formalin-fixed and paraffin-embedded.
Isolation of Total RNA and qRT-PCR
Total RNA was isolated using an RNeasy plus mini 
kit (Qiagen, Valencia, CA ) following the manufacturer pro-
tocol. One-step RT-PCR (reverse transcription-polymerase 
chain reaction) kit with SYBR green was used for amplifi-
cation of total RNA (75 ng) following the manufacturer’s 
protocol (BioRad) and our recent publication.32 The primers 
sequences used for GAPDH (116 bp) and CRM1 (198 bp) 
are 5′-GGTGGTCTCCTCTGACTTCAACA-3′ (forward) 
and 5′-GTTGCTGTAGCCAAATTCGTT GT-3′ (reverse), 
and 5′-GGAACCAGTGCGAAGGAATA-3′ (forward) and 
5′-TTTCGCTGGTCCTACTTGCT-3′ (reverse), respectively. 
Threshold cycle number (Ct value) was analyzed using CFX 
Manager Software (Bio-Rad, Hercules, CA). The Ct value of 
CRM1 was normalized to the Ct value of GAPDH from same 
sample and the fold change in the expression was calculated 
by using the ΔΔCt method. Amplification reaction for each 
sample was performed in triplicates. Nontemplate control was 
also included in each experiment.
Array-Based SYBR Green RT-PCR
Constitutive gene expression profiling was performed 
using the RT2 Profiler PCR array to analyze the expression of 
84 genes involving in cancer signal pathways (Human Cancer 
Drug Targets, Qiagen) based on manufacturer’s instructions 
and our previous publications.33,34 Experiment was performed 
in duplicate for each group.
Cell Viability Assay
Cell viability was evaluated using the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay as previously described.29,33 Based on the cyto-
toxicity of LMB observed in our previous reports,33,34 0.5 nM 
LMB was selected for cotreatment. Experiments were per-
formed independently in triplicate.
Analysis of Cell Cycle by Flow Cytometry
The cells were harvested after 24 and 48 h of treatment. 
Based on the cell viability assay, a total of four groups of A549 
cells with different treatment types were analyzed, including 
control, 25 μM cisplatin (Cis25), 0.5 nM LMB (LMB0.5), and 
25 μM cisplatin + 0.5 nM LMB (Cis25+LMB0.5). Cell cycle 
analysis was conducted by a Guava EasyCyte Flow Cytometer 
(Millipore, San Diego, CA) as previously described.32,33 Each 
sample was run in triplicate and each experiment was repeated 
three times.
Western Blot Analyses
Protein expression levels in A549 cells after cisplatin 
treatment (0, 10, and 25 μM) with or without LMB (0.5 nM) 
were evaluated by Western blots as previously described.29,32,33 
Immunoblotting was performed using different primary anti-
bodies and α-tubulin as the internal control.
Xenograft Animal Model
The handling of animals was in accordance with the 
Institutional Animal Care and Use Committee. Female athymic 
mice, 7–8 weeks of age and 23.5 g in weight (Charles River 
Laboratory, Waltham, MA) received subcutaneous injection of 
1 × 106 A549 or A549
CRM1-
 cells in the lower flank (n = 8/group). 
Tumor volume was measured by a digital caliper (Thermo 
Fisher Scientific). The major longitudinal diameter (length) 
and the major transverse diameter (width) were determined. 
Tumor volume was calculated based on caliper measurements 
by the following formula: tumor volume = ½ (length × width).2
Treatment of Mouse Xenografts
Thirty-two female athymic mice, 7–8 weeks of age and 
23.5 g in weight (strain code 088, Charles River Laboratory) 
were each injected subcutaneously with 1 × 106 lung cancer 
A549 cells in the lower flank. The mice bearing lung cancer 
xenografts were divided into four study groups and intra-
tumorally injected with the following treatments: (1) 0.9% 
saline (vehicle control, n = 8); (2) LMB (2 μg/kg, n = 8); 
(3) Cis (2.5 mg/kg, n = 8); and (4) Cis (2.5 mg/kg) + LMB 
(2 μg/kg) (Cis + LMB, n = 8). All injections were carried out 
for three times per week. Mice body weights and tumor sizes 
were measured three times per week.
Statistical Analyses
Paired t test, Student t test, one-way analysis of variance 
and posthoc tests, factorial analysis of variance, and χ2 test 
were used to compare the difference between groups where 
appropriate. All analyses were performed using the STATA 
9.0 software. Differences with p value less than 0.05 were 
considered statistically significant.
RESULTS
CRM1 Expression in Lung Tumors from 
Lung Cancer Patients and Mice Treated 
with NNK and in BEAS-2BNNK
Immunohistochemistry of CRM1 was first performed 
on a training set of 10 lung tumor tissues from smokers and 
10 matched tumor-adjacent histologically normal lung tissues 
(Fig. 1A). CRM1 expression level was significantly higher 
in lung tumor tissues (H score: 139.9 ± 11.7), compared 
with matched normal tissues (H score: 83.9 ± 11.8; Fig. 1B, 
p = 0.006, paired t test). To validate this result further, CRM1 
expression was performed using TMA on a testing set of 59 
lung tumor tissues and their matched adjacent histologically 
normal tissues. CRM1 expression level was significantly 
higher in tumor tissues, compared with the matched nor-
mal tissues (2.3 ± 0.7 in cancer versus 0.7 ± 0.5 in normal, 
p < 0.001, paired t test, Fig. 1C). Therefore, CRM1 is overex-
pressed in lung tumor tissues of NSCLC, the major histologic 
type of lung cancer from smokers.
For comparison, lung adenocarcinoma is the 
only lung tumor subtype found in FBV/N mice treated 
with NNK (Fig. 1D). Western blot analysis was per-
formed for eight of such lung tumors and lung tissues 
from the control. The data showed an increased CRM1 
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expression in the tumor tissues compared with the normal tissues 
(Fig. 1E, p < 0.01). To investigate the effects of a lung car-
cinogen on the expression of CRM1 in vitro, BEAS-2B 
cells were transformed with NNK (BEAS-2B
NNK
). Soft 
agar colony assay showed a significant increase in both col-
ony number and colony size in BEAS-2B
NNK
 as compared 
with vehicle-treated BEAS-2B cells (Fig. 2A, p < 0.05). 
Furthermore, the transformed cells showed a significant 
increased CRM1 expression both at the mRNA (2.6-folds) 
and protein (approximate 1.5-folds) levels as compared 
with vehicle-treated BEAS-2B cells (Fig. 2B, p < 0.05). 
Therefore, CRM1 is overexpressed in lung tumors from 
both lung cancer patients and mice treated with the tobacco 
smoke carcinogen NNK, as well as NNK-transformed lung 
epithelial cells.
p53 Phosphorylation in Lung Tumors 
from NNK-Treated Mice and in NNK-
Transformed Lung Epithelial Cells
CRM1 plays an important role in the transport of tumor 
suppressor and oncogene proteins, including p53, from the cell 
nucleus into the cytoplasm.35,36 Our previous study found p53 
phosphorylation at Thr55 involved in CRM1-mediated p53 trans-
port to the cytoplasm after treatment of A549 cells with LMB.33 
BEAS-2B
NNK
 cells overexpressed phosphorylated-p53 (p-p53) 
FIGURE 1.  CRM1 expression in 
lung tumors from human lung 
cancer patients and NNK-induced 
lung adenocarcinoma in mice. A, 
IHC staining of CRM1 in lung ade-
nocarcinoma and matched adja-
cent histologically normal lung 
tissues from a lung cancer patient 
(40×). B, Quantitive H score of 
CRM1 expression in lung tumors 
and matched adjacent normal 
lung tissues (n = 10). *p < 0.01 
compared with adjacent normal. 
C, Quantitative measurement of 
CRM1 expression in lung tumors 
and matched adjacent normal 
lung tissues from tissue microarray 
(n = 59). *p < 0.01 compared with 
adjacent normal. D, Hematoxylin 
and eosin staining (40×) of a case 
of lung adenocarcinoma from 
NNK-treated mice. E, CRM1 pro-
tein expression of four representa-
tive cases of lung adenocarcinoma 
from NNK-treated mice (n = 8) 
and four representative normal 
lung tissues from vehicle-treated 
controls (n = 8) from the same 
Western blot. The blot was probed 
for α-tubulin to confirm equal pro-
tein loading. *p < 0.01 compared 
with the control. CRM1, chromo-
some region maintenance 1; IHC, 
immunohistochemistry.
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at Thr55 (Fig. 2B). We determined that p53 mutations were not 
detected in the lung adenocarcinoma from NNK-treated mice 
used in this study as the occurrence of such mutations would 
lead to an accumulation of nonfunctional mutant p53 in these tis-
sues (data not shown). Western blot analysis showed a significant 
increase in p-p53 at Thr55 in lung tumors from NNK-treated mice 
from the same tumors analyzed above for CRM1, compared with 
the normal lung tissues (Fig. 2C; p < 0.01). We have previously 
shown that CRM1 protein expression was decreased, and p53 
posttranslational modifications were also changed (but the spe-
cific residues were not characterized) in BEAS-2B cells at an 
early exposure to NNK (at 10, 75, and 150 µM) for 24 and 72 h.29 
Protein expression levels of p-p53 at Thr55 in these exposed cells 
were therefore further analyzed and showed a dose-dependent 
decrease as compared with the matched control BEAS-2B cells 
treated with the vehicle (p < 0.05, Fig. 2D).
FIGURE 2.  Soft agar colony assay and CRM1 and phospho-p53 expressions in BEAS-2B cells after NNK exposure. A, Soft 
agar colony assay of BEAS-2B cells and NNK-transformed BEAS-2B cells (BEAS-2BNNK; 40×). B, CRM1 and phospho-p53 (Thr55) 
protein expression in BEAS-2B cells and BEAS-2BNNK cells. *p < 0.05 compared with BEAS-2B. C, Phospho-p53 (Thr55) protein 
expression of four representative cases of lung adenocarcinoma from NNK-treated mice (n = 8) and four representative normal 
lung tissues from vehicle-treated controls (n = 8) from the same Western blot. The blot was probed for α-tubulin to confirm 
equal protein loading. *p < 0.01 compared with the control. D, Phospho-p53 (Thr55) expression in BEAS-2B cells exposed to 
NNK or vehicle control for 24 and 72 h. Data were obtained from representative samples loaded on the same Western blot for 
each of 24 and 72 h. Blots were probed for α-tubulin to confirm equal protein loading. *p < 0.05 compared with the control. 
CRM1, chromosome region maintenance 1.
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Cellular Transformation in BEAS-2BCRM1+,  
Decreased Colony Formation in A549CRM1-,  
and Delayed Tumor Growth after A549CRM1-  
Implantation in the Xenograft Nude Mouse Model
Over a sixfold increase of CRM1 expression level was 
observed in BEAS-2B
CRM1+
 cells as compared with control 
BEAS-2B cells (Fig. 3A). Immunocytochemistry analyses 
showed that CRM1 expression was remarkably higher and 
p53 nuclear staining was significantly decreased in BEAS-
2B
CRM1+
 compared with BEAS-2B cells (data not shown). 
BEAS-2B
CRM1+
 cells were prone to form colonies in a regular 
culture condition (Fig. 3B). Soft agar colony assay showed 
an increase in both colony number and size in BEAS-
2B
CRM1+
 cells as compared with the control BEAS-2B cell 
FIGURE 3.  CRM1 protein expression 
and soft agar colony assay in BEAS-2B, 
BEAS-2BCRM1+, A549, and A549CRM1- cells, 
and tumor growths in xenograft nude 
mice implanted with A549 or A549CRM1- 
cells. A–C, CRM1 protein expression (A), 
cell morphology (B, 100×), and soft agar 
colony assay (C, 40×) in BEAS-2B and 
BEAS-2BCRM1+ cells. The blot was probed 
for α-tubulin to confirm equal protein 
loading. *p < 0.01 compared with 
BEAS-2B. D–F, CRM1 protein expression 
after CRM1-siRNA (D) and CRM1-shRNA 
(E) transfection and soft agar colony 
assay (F, 40×) in A549 and A549CRM1- 
cells. Blots were probed for α-tubulin to 
confirm equal protein loading. *p < 0.05 
compared with A549. G, Tumor growths 
in xenograft nude mice (strain code 088) 
implanted with A549 or A549CRM1- cells. 
CRM1, chromosome region mainte-
nance 1; shRNA, short hairpin siRNA.
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groups (Fig. 3C, number of colonies: 54.7 ± 10.2/area for 
BEAS-2B
CRM1+
 and 16.3 ± 5.6/area for BEAS-2B, p < 0.01; 
size/colony (μm2): 3136.1 ± 306.7 for BEAS-2B
CRM1+
 and 
1010.5 ± 437.6 for BEAS-2B, p < 0.01). These results indi-
cate that CRM1 by itself may play a critical role in the in vitro 
cellular malignant transformation of lung epithelial cells.
Our designed CRM1-siRNA could significantly knock-
down CRM1 in A549 (Fig. 3D), and the efficiency of this single 
target-specific siRNA is similar and even better to that of com-
mercial CRM1-siRNA products consisting of pools of three 
to five target-specific siRNAs (data not shown). Knockdown 
of CRM1 expression in A549
CRM1-
 was confirmed by qRT-
PCR (greater than 40% decreases) and Western blot (Fig. 3E). 
Soft agar assay revealed a decrease in both number and size 
of colonies in A549
CRM1-
 cells as compared with A549 cells 
(Fig. 3F, number of colonies: 29.3 ± 3.7/area for A549
CRM1-
 
and 33.4 ± 5.7/area for A549, p<0.05; size/colony (μm2): 
2236.1 ± 273.5 for A549
CRM1-
 and 3169.3 ± 235.8 for A549, 
p < 0.01). No differences in the CRM1 expression level and 
colony formation were observed between A549 cells without 
vector transfection and A549 cells transfected with scramble 
vector (data not shown). Figure 3G displays the tumor growth 
curve for the nude mice (strain code 088) implanted with 
A549
CRM1-
 or A549 cells. Although tumor growth was observed 
in mice injected with either A549
CRM1-
 or A549 cells, signifi-
cantly delayed tumor growth was observed in mice injected 
with A549
CRM1-
 as compared with those injected with A549 
(p < 0.05). No difference of the body weight and behavior was 
observed in the mice implanted with A549
CRM1-
 or A549 (data 
not shown). These data were further confirmed in another xeno-
graft nude mouse model (strain code 490, data not shown).
Effects of Cis and/or LMB on Cytotoxicity  
and Cell Cycle
The cytotoxic effects of Cis alone or Cis + 0.5 nM LMB 
(a very low nontoxic dose) on A549 and/or A549
CRM1-
 cells 
were evaluated. Cis alone significantly inhibited the prolifera-
tion of both A549 and A549
CRM1-
 in a dose- and time- depen-
dent manner (p < 0.001). Furthermore, A549
CRM1-
 cells were 
even more sensitive to Cis than A549 cells (Fig. 4A; p < 0.05). 
In addition, cotreatment with Cis and LMB significantly 
increased the cytotoxic effects of Cis on A549 cells (Fig. 4B; 
p < 0.05). These data indicate that inhibition of CRM1 plays an 
important role in chemo-sensitizing cancer cells, and target-
ing CRM1 using LMB provides a novel and efficient adjunct 
therapy for lung cancer treatment. Cell proliferation inhibition 
could be the consequence of cell cycle arrest. The cell cycle 
analysis by flow cytometry of the four treated groups of A549 
cells showed as expected that LMB0.5 treatment did not alter 
the cell cycle distribution of A549 cells, compared with the 
control. However, the Cis25 and Cis25 + LMB0.5 treatment 
groups resulted in a significantly higher proportion of cells 
in S and G2/M phases at both 24 and 48 h, compared with the 
control (p < 0.05, Fig. 4C). Moreover, the Cis25 + LMB0.5 
treatment group showed an accumulation of a significantly 
higher proportion of cells in the G2/M phase, but a signifi-
cantly lower proportion of cells in the S phase at both 24 and 
48 h, compared with Cis25 (p < 0.05, Fig. 4C).
Gene Expression Alterations after Cis and 
Cis + LMB Treatment and Western Blot 
Analyses of PARP1, p21, and Survivin
From the 84 genes analyzed (Fig. 5A), there is a sig-
nificantly decreased expression level of eight genes (AURKA, 
FIGURE 4.  The effects of Cis and/or LMB on cytotoxicity and 
cell cycle distribution. A, Cytotoxic effects of Cis on A549 or 
A549CRM1- cells at 24–72 h. Data are expressed as the percentage 
by comparing to vehicle control. Values are represented as mean 
± SD, n = 6. Experiments performed in triplicate yielded similar 
results. B, Cytotoxic effects of Cis and/or LMB on A549 cells at 
24–72 h. Data are expressed as the percentage by comparing 
with vehicle control for Cis and LMB for Cis + LMB. Values are 
represented as mean ± SD, n = 6. Experiments performed in 
triplicate yielded similar results. C, Distribution of cell popula-
tion in different cell cycle phases in A549 after Cis and/or LMB 
treatment. Experiments were performed in triplicate and yielded 
similar results. Cis25: 25 μM cisplatin, LMB0.5: 0.5 nM LMB, and 
Cis25 + LMB0.5: 25 μM cisplatin + 0.5 nM LMB. LMB, leptomy-
cin B; CRM1, chromosome region maintenance 1.
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AURKB, CDK1, HIF1A, MDM4, PLK1, PLK4, and TNKS) 
and an increased expression of four genes (CTSB, GRB2, 
MDM2, and NF-κB) in the Cis25 group compared with the 
control (Fig. 5A; p < 0.05). Cis25 + LMB0.5 treatment sig-
nificantly increased the expression level of AURKA, HDAC8, 
PARP2, and TNKS and decreased the expression level of 
GRB2 and RHOA as compared with the Cis25 group (Fig. 5A; 
p < 0.05). No significant difference in the gene expression 
profile was observed in LMB0.5 group, compared with the 
control group (data not shown), which is in line with the 
FIGURE 5.  The effects of Cis and/or LMB on gene/protein expression. A, A representative PCR array gene table and RT-PCR 
gene arrays in A549 cells treated with Cis or Cis + LMB. The heat map demonstrating fold regulation expression data. Gray 
Genes were not measurable. Cis25: 25 μM cisplatin, and Cis25 + LMB0.5: 25 μM cisplatin + 0.5 nM LMB. B, Western blot analy-
ses of PARP1, p21, and survivin protein expression in A549 cells after Cis and/or LMB treatment. Blots were probed for α-tubulin 
to confirm equal protein loading. RT-PCR, reverse transcription-polymerase chain reaction. LMB, leptomycin B.
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observation of no differences in cell cycle progression profile 
between these two treatment groups. qRT-PCR for HIF1A, 
GRB2, MDM2, and PARP2 were further performed and 
the results helped confirm the RT-PCR array data (data not 
shown).
The protein expressions of PARP1, p21, and survivin 
were then analyzed because of their significant roles in DNA 
damage, cell cycle, and apoptosis in response to chemothera-
peutic agents. Expression levels of PARP1 and p21 were sig-
nificantly increased in a dose-response manner at both 24 and 
48 h after treatment in both the Cis or Cis + LMB treatment 
groups, compared with those of vehicle-treated cells (Fig. 5B; 
p < 0.05). Furthermore, the up-regulation of PARP1 in Cis + 
LMB was significantly higher, compared with the Cis group 
(Fig. 5B; p < 0.05). On the other hand, the survivin expression 
level was significantly decreased in cells treated with Cis or 
Cis + LMB, compared with those of controls at both 24 and 
48 h after treatment (Fig. 5B; p < 0.05).
Tumor Growth after Treatment with Cis and/
or LMB in the Xenograft Nude Mouse Model
Figure 6A displays the tumor growth curve for each 
of the treatment conditions. Tumors injected with Cis sig-
nificantly delayed tumor growth, compared with the vehicle-
treated control (p < 0.01). Although growth curves followed a 
similar trend for the tumor treated with either LMB alone or 
vehicle control, tumors treated with Cis + LMB significantly 
delayed tumor growth starting at the beginning of the treat-
ment as compared to the Cis group (p < 0.05). These data 
demonstrate the synergistic effect of the Cis + LMB cotreat-
ment. Two weeks after treatment with Cis or Cis + LMB, the 
body weight for mice started to decrease gradually (Fig. 6B) 
but without deteriorating their behavior and health condition.
DISCUSSION
We have demonstrated that CRM1 were frequently over-
expressed in NSCLC, particularly adenocarcinoma and squa-
mous cell carcinoma, the two major subtypes of lung tumors 
from lung cancer patients, suggesting that CRM1 overexpres-
sion is involved in lung carcinogenesis. Similar results were 
observed in lung adenocarcinoma from NNK-treated mice. 
Furthermore, our data showed that CRM1 overexpression in 
lung epithelial cell line BEAS-2B following NNK exposure 
or transfection with CRM1 vector resulted in cellular trans-
formation, suggesting that up-regulation of CRM1 is likely 
one important pathway of cellular malignant transforma-
tion. Our data also demonstrated a synergistic effect on in 
vitro cell growth and in vivo tumor growth following CRM1 
knockdown/inhibition in combination with standard chemo-
therapeutics with underlying specific differential gene/pro-
tein expression patterns. These results indicate a therapeutic 
potential of targeting CRM1 for lung cancer treatment.
Increased CRM1 expression has been reported previ-
ously in other tumor types, including cervical,26 ovarian,24 and 
pancreatic23 cancers, glioma,25 and osteosarcoma27 and was 
associated with a negative prognosis. To the best of our knowl-
edge, this is the first study showing CRM1 overexpression in 
lung cancer. It is now well known that CRM1 is involved in 
nuclear-cytoplasmic transport of various cancer-associated 
“cargo” proteins, such as p53, and other proteins, including 
p21, p27, EGFR, Akt1, and survivin.17–20 The observed CRM1 
overexpression could in turn lead to dysfunction/inactivation 
of tumor suppressor proteins or activation of pro-oncogenes 
by shuttling them out of nucleus to cytoplasm. For instance, 
besides p53 mutation, another important pathway to p53 
regulation/dysregulation is through posttranslational modi-
fications, including phosphorylation of wild-type p53 and a 
subsequent alteration in its subcellular localization and func-
tion.36,37 Phosphorylation at some of such sites is critical for 
shuttling p53 from the nucleus to cytoplasm to assume its 
diverse functions. For instance, the phosphorylation at Thr55 
is required for MDM2 to promote the CRM1 and p53 interac-
tion and the export of p53 to the cytoplasm, leading to p53 deg-
radation and a decrease in G1 arrest of the cell cycle, whereas 
inhibition of Thr55 phosphorylation restored the p53 nuclear 
localization.35 We showed that Thr55 of p53 protein was phos-
phorylated not only in lung tumors from NNK-treated mice 
but also in BEAS-2B cells that were transformed following 
NNK-exposure. Furthermore, these tumors and transformed 
FIGURE 6.  The effects of Cis and/or LMB on tumor growth 
(A) and body weight (B) in xenografted nude mice (strain 
code 088). The Cis-treated group showed a significant 
decrease in tumor growth compared with the vehicle treated 
group. The Cis + LMB group demonstrated a significant 
decrease in tumor growth compared with the Cis-treated 
group. Vehicle control: 0.9% saline (n = 8), LMB: 2 μg/kg 
(n = 8), Cis: 2.5 mg/kg (n = 8), and Cis + LMB: Cis (2.5 mg/
kg) + LMB (2 μg/kg; n = 8). LMB, leptomycin B.
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cells showed CRM1 overexpression, suggesting a mechanism 
of lung carcinogenesis involving CRM1 overexpression and 
inactivation of p53 by posttranslational phosphorylation of 
Thr55 in lung carcinogenesis.
Data from our in vitro studies using BEAS-2B cells 
showed a biphasic response of cells to NNK. The initial phase 
of decrease in CRM1 expression in NNK-exposed cells was 
observed in our previous study.29 In this study, we further 
showed that p-p53 (Thr55) expression was also decreased 
during this initial phase that may correspond to an adaptive 
response for cellular repair of NNK-induced DNA damage. 
Indeed, we have previously observed that following the expo-
sure of BEAS-2B cells with NNK there was an accumulation 
of p53 in the nucleus and activation of p21 that is important 
for the process of cell cycle arrest to allow repair of DNA 
damage.29 Therefore, decrease in both CRM1 and p-p53 at 
Thr55 would lead to a decrease in export of p53 and a nuclear 
accumulation of p53 during the early phase of NNK expo-
sure. Different from this early phase of cellular response to 
the tobacco carcinogen NNK, in which CRM1 was decreased 
and concomitantly p53 accumulated in the nucleus probably 
as a result of an adaptive response to DNA damage repair, 
we further demonstrated in this study that in the later stage 
of NNK exposure, there were increased expression levels of 
CRM1 and p-p53 at Thr55 in both BEAS-2B
NNK
 cells and lung 
tumors. It has been proposed that a shared complex regula-
tory loop may exist between CRM1 and p53, and p53 could 
repress CRM1 promoter activity by interfering with the tran-
scription factor, nuclear factor Y.38 Although our results sug-
gest that NNK-mediated p53 phosphorylation at Thr55 works 
in parallel with CRM1 expression not only in early phase of 
NNK exposure but also in NNK-induced cellular transforma-
tion, the underlining mechanisms are not clear. On the other 
hand, the data from our transfection experiments indicate that 
exogenous CRM1 modulation by either overexpression in 
BEAS-2B or knockdown in A549 did not significantly alter 
expression of p-p53 at Thr55 (data not shown). Therefore, p53 
may directly affect CRM1 in NNK-induced carcinogenesis 
but not vice versa, and further study is needed to elucidate 
this possibility.
Cisplatin is commonly used to treat various types of 
cancers, including lung cancer. In our study, significant alter-
ations in the expression of genes from protein kinases, cell 
cycle, transcription factors, and apoptosis were found in A549 
cells treated with cisplatin. However, drug resistance in cispl-
atin-containing regimens is a major issue that prevents better 
response rates.39 As cisplatin constitutes a major therapeutic 
option in clinical settings, the development of chemosensiti-
zation strategies for cisplatin has important clinical implica-
tions. In this study, blocking CRM1 expression significantly 
improves cancer cell sensitization to Cis as revealed by the fact 
that the drug was more potent in A549
CRM1-
 cells than in A549 
cells and that CRM1 inhibition by a co-treatment with Cis + 
LMB further improved the efficacy of cisplatin in suppressing 
lung cancer cell proliferation. Thus, combined chemotherapy 
could be an effective and clinically practical strategy for inter-
fering with chemoresistance. Genes, such as survivin, BAX, 
BCL2, p53, NF-κB, and ERBB2 are frequently involved in 
the pathways that sustain cisplatin resistance.39,40 In lines with 
these findings, we observed in this study an increased expres-
sion of NF-κB after treatment with Cisplatin alone while a 
decreased NF-kB expression in the Cis + LMB treatment. 
Moreover, p21 and survivin are well known to play a criti-
cal role in cell cycle and survival signaling.41,42 Accordingly, 
we observed a significant dose-dependent increase in p21 
and decrease in survivin expression in cells treated with Cis 
alone and a more pronounced decrease in survivin in Cis + 
LMB, compared with Cis treatment alone. In fact, NF-κB is 
a transcription factor that regulates the expression of numer-
ous genes that are critical for survival, for instance, survivin.43 
NF-κB could be activated by various stimuli such as proin-
flammatory cytokines, cellular stress, as well as chemother-
apeutic agents.43 Therefore, the inhibition of NF-κB by Cis 
+ LMB leading to a further decrease in survivin compared 
with Cis alone could be partially responsible for the syner-
gistic effect in A549 lung cancer cells. Finally, the observed 
changes of other genes such as RHOA, GRB2, and PARP2 
in cells treated with Cis + LMB, compared with cells treated 
with Cis alone, could result in enhancing the sensitization of 
A549 cells to Cis + LMB treatment on cell proliferation.44–46
Although the phase I clinical trial of LMB was unsuc-
cessful, the detailed review of this trial only mentions some 
malaise and anorexia as side effects, which are common for 
most effective chemotherapeutic drugs.47 These side effects 
may diminish if lower doses are administered. In view of the 
novel CRM1 inhibitors now being developed by different 
pharmaceutical companies,17,48–50 we believe that the clinical 
usage of LMB deserves a thorough re-evaluation, especially 
in combination with other chemotherapeutic drugs at a low 
and nontoxic dose. Our recent studies have suggested that 
abrogation of CRM1 through LMB could inhibit lung cancer 
cell growth and induce cytotoxicity in lung cancer cells, with 
minimal effects on normal bronchial epithelial cells,34 and 
the combined therapy using initial doxorubicin treatment and 
subsequent LMB treatment could improve the effectiveness of 
therapeutic strategy for lung cancer treatment.33 The selective 
and potent antitumor cytotoxicity was further confirmed by 
the silencing of CRM1 using siRNA (data not shown). The 
finding from our in vivo xenograft nude mouse model in this 
study first demonstrated that CRM1 knockdown diminishes 
the tumorigenicity of lung cancer cells. In addition, the imple-
mentation of a very small and nontoxic dose of LMB could 
boost the efficacy of cisplatin. This combinative chemother-
apy showed no additional side effects. Therefore, adding LMB 
to the treatment protocol could be another effective and clini-
cally practical strategy to not only reduce the drug side effects 
but also enhance their efficacy, especially in advanced lung 
cancer, which is characterized by tumor chemoresistance.
In summary, our results suggest that CRM1 overex-
pression is cooperating with p53 phosphorylation in cellular 
malignant transformation, a crucial step in lung carcinogen-
esis. CRM1 inhibition could sensitize the efficacy of cispla-
tin for lung cancer treatment. As an affirmative, CRM1 may 
serve as a useful molecular target in clinical protocols for lung 
cancer treatment. Future clinical trials are warranted to imple-
ment this novel therapeutic strategy.
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